Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) Emerging Therapy and TPP Insights

Thelansis’s “Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) Overview

Relapsed or refractory peripheral T‑cell lymphoma (r/r PTCL) is an aggressive and heterogeneous group of mature T‑cell non‑Hodgkin lymphomas that remain difficult to treat, as patients who relapse after initial therapy or fail to respond to frontline regimens have poor outcomes and limited long‑term survival. Conventional salvage chemotherapy offers low response rates, and only a minority of patients are eligible for potentially curative stem cell transplantation. Approved single‑agent therapies such as pralatrexate, romidepsin, and belinostat provide modest benefit, while newer approaches—including histone deacetylase inhibitors, antifolate agents, monoclonal antibodies, and immunotherapies—are under investigation. Despite these options, no consensus standard of care exists, and prognosis remains guarded, underscoring the importance of clinical trial enrollment and the urgent need for novel, disease‑modifying therapies that target the complex biology of r/r PTCL to improve durability of response and overall survival.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025